SEC asks Biocon to submit safety, mortality data for Itolizumab
The company claims that approximately 2000 COVID-19 patients used the drug under the emergency use authorisation
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.